Bicara Therapeutics Inc.

Bicara Therapeutics Inc. is a clinical-stage biopharmaceutical company dedicated to developing transformative bifunctional therapies for patients with solid tumors. Headquartered in Boston, Massachusetts, the company's mission is to improve the lives of individuals living with cancer by delivering innovative, first-in-class treatments designed to provide meaningful and durable benefits.

The company's lead program is ficerafusp alfa (BCA101), a first-in-class, dual-action, bifunctional antibody that targets both the epidermal growth factor receptor (EGFR) and transforming growth factor beta (TGF-β). This therapeutic candidate is currently in clinical development for various solid tumor cancer types, with a primary focus on head and neck squamous cell carcinoma (HNSCC).

Recent notable developments include the U.S. Food and Drug Administration (FDA) granting Breakthrough Therapy Designation to ficerafusp alfa in combination with pembrolizumab for first-line HPV-negative recurrent or metastatic HNSCC in October 2025. In March 2026, Bicara Therapeutics announced the selection of the optimal Phase 3 dose for ficerafusp alfa in this indication and initiated its Phase 3 study. The company also completed an oversubscribed public offering in February 2026, generating approximately $172.5 million in gross proceeds, and reported a strong cash position of $414.8 million as of December 31, 2025, with additional funding secured in Q1 2026 to extend operations into the first half of 2029. The leadership team includes CEO Claire Mazumdar Clemon, President & COO Ryan Cohlhepp, and CFO Ivan Hyep.